Merck & Co. (MRK)

Financing Cash Flow

$6.17B

TTM · Period ending: · USD

MRK logo

MRK Financing Cash Flow

Latest reported$6.17B
MRK TTM Cash from Financing (-$953.70M → $6.17B)
High-resolution chart · PNG

MRK financing cash flow history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Merck & Co. Financing Cash Flow — Trailing twelve months (TTM) (USD)
Period endingFinancing Cash Flow (USD)
6,170,000,000
852,000,000
-1,922,000,000
-9,682,000,000
-14,745,000,000
-9,973,000,000
-7,032,000,000
-6,268,000,000
-8,112,000,000
-5,570,000,000
-4,810,000,000
-4,119,000,000
-2,552,000,000
-8,087,000,000
-9,119,000,000
-2,358,000,000
-1,930,000,000
1,605,000,000
2,593,000,000
-1,242,000,000
-2,819,000,000
-3,440,000,000
-2,832,000,000
-6,215,000,000
-5,516,000,000
-8,737,000,000
-8,861,000,000
-12,416,000,000
-11,169,000,000
-12,052,000,000
-13,160,000,000
-13,379,000,000
-10,938,000,000
-14,189,000,000
-10,006,000,000
-6,198,000,000
-7,569,000,000
-4,732,000,000
-9,044,000,000
-9,473,000,000
-11,177,000,000
-13,393,000,000
-5,387,000,000
-12,624,000,000
-8,806,000,000
-11,578,000,000
-15,113,000,000
-8,094,000,000
-12,288,000,000
-2,949,000,000
-5,990,000,000
-4,584,000,000
-2,407,000,000
-3,963,000,000
-3,267,000,000
-4,280,000,000
-5,786,000,000
-6,457,000,000
-6,904,000,000
-5,967,900,000
-5,348,900,000
-7,555,200,000
-5,441,000,000
-5,995,500,000
-6,742,900,000
-304,200,000
-1,638,300,000
-1,544,300,000
932,700,000
-2,330,800,000
-5,522,500,000
-5,162,200,000
-6,531,300,000
-7,233,400,000
-4,866,100,000
-3,891,400,000
-4,130,200,000
-4,598,800,000
-5,604,200,000
-5,533,800,000
-4,997,300,000
-4,700,400,000
-3,040,400,000
-5,079,000,000
-5,154,100,000
-5,269,900,000
-5,591,400,000
-7,531,600,000
-8,367,000,000
-7,952,700,000
-6,827,900,000
-4,705,300,000
-4,219,700,000
-5,177,400,000
-5,531,900,000
-5,019,800,000
-5,815,800,000
-3,852,000,000
-5,071,200,000
-3,710,900,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.